LungLife AI, INC Result of AGM (4930Y)
May 04 2023 - 12:49PM
UK Regulatory
TIDMLLAI
RNS Number : 4930Y
LungLife AI, INC
04 May 2023
LungLife AI, Inc.
(the "Company" or "LungLife")
Result of Annual General Meeting
LungLife AI (AIM: LLAI), a developer of clinical diagnostic
solutions for lung cancer, announces that at its Annual General
Meeting , held at earlier today, all 10 resolutions put to members
were passed on a poll.
The number of votes lodged by proxy for and against each of the
resolutions proposed, and the number of votes withheld was as
follows:
Resolution Votes for % Votes against % Votes withheld
Resolution 1 ( Common
)
TO receive the Annual Report
and Accounts of the Company
for the year ended 31 December
2022 together with the
directors' and auditor's
reports thereon. 13,016,289 100.00 0 0.00 0
----------- ------- -------------- ------ ---------------
Resolution 2 ( Common
)
TO approve the Directors'
Remuneration Policy. 9,997,926 76.81 3,018,363 23.19 0
----------- ------- -------------- ------ ---------------
Resolution 3 ( Common
)
TO receive the Directors'
Remuneration Report for
the year ended 31 December
2022. 13,016,289 100.00 0 0.00 0
----------- ------- -------------- ------ ---------------
Resolution 4 ( Common
)
THAT Roy Davis be, and
hereby is, re-elected as
a director of the Company
to hold office until the
conclusion of the next
Annual General Meeting
of the Company. 13,016,289 100.00 0 0.00 0
----------- ------- -------------- ------ ---------------
Resolution 5 ( Common
)
THAT Paul Pagano be, and
hereby is, re-elected as
a director of the Company
to hold office until the
conclusion of the next
Annual General Meeting
of the Company. 13,016,289 100.00 0 0.00 0
----------- ------- -------------- ------ ---------------
Resolution 6 ( Common
)
THAT David Anderson be,
and hereby is, re-elected
as a director of the Company
to hold office until the
conclusion of the next
Annual General Meeting
of the Company. 13,016,289 100.00 0 0.00 0
----------- ------- -------------- ------ ---------------
Resolution 7 ( Common
)
THAT Andrew Boteler be,
and hereby is, re-elected
as a director of the Company
to hold office until the
conclusion of the next
Annual General Meeting
of the Company. 13,016,289 100.00 0 0.00 0
----------- ------- -------------- ------ ---------------
Resolution 8 ( Common
)
THAT Sara Barrington be,
and hereby is, re-elected
as a director of the Company
to hold office until the
conclusion of the next
Annual General Meeting
of the Company. 13,016,289 100.00 0 0.00 0
----------- ------- -------------- ------ ---------------
Resolution 9 (Common)
THAT James McCullough be,
and hereby is, re-elected
as a director of the Company
to hold office until the
conclusion of the next
Annual General Meeting
of the Company. 13,016,289 100.00 0 0.00 0
----------- ------- -------------- ------ ---------------
Resolution 10 ( Common
)
THAT Crowe UK LLP be, and
hereby is, reappointed
as auditor of the Company
to hold office until the
conclusion of the next
Annual General Meeting
of the Company. 13,016,289 100.00 0 0.00 0
----------- ------- -------------- ------ ---------------
The Company notes that, whilst Resolution 2 was passed with the
required majority, there was a sizable vote against it representing
23.19% of shareholders who voted. The Company acknowledges these
votes and will engage with shareholders to understand further the
reasons behind this vote. The Board will provide an update on this
engagement and any actions taken will be published within six
months of the AGM.
As at 4 May 2023, there were 25,485,982 common shares in issue.
Stockholders are entitled to one vote per common share. Votes
withheld are not votes in law and so have not been included in the
calculation of the proportion of votes for and against a
resolution.
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970
& J oint Broker)
Virginia Bull / Cameron MacRitchie
/ Lydia Zychowska
Goodbody (Joint Broker) Tel: +44 (0) 20 3841 6202 / +353 (1)
Tom Nicholson / Stephen Kane 667 0420
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Stephanie Cuthbert / Alice Woodings Mob: 07980 541 893 / 07407 804 654 /
/ Phillip Marriage 07867 984 082
About Lunglife AI
LungLife AI is a developer of clinical diagnostic solutions
designed to make a significant impact in the early detection of
lung cancer, the deadliest cancer globally. Using a minimally
invasive blood draw, the Company's LungLB(R) test is designed to
deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit
www.lunglifeai.com . Our Purpose is to be a driving force in the
early detection to lung cancer. Our Vision is to invert the 20:80
ratio such that in years to come at least 80% of lung cancer is
detected early.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGEAKSLELPDEFA
(END) Dow Jones Newswires
May 04, 2023 12:49 ET (16:49 GMT)
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Oct 2023 to Oct 2024